Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative study of the efficacy and safety of vaginally applied Dequalinium Chloride (10 mg) and orally applied Metronidazole (2 x 500 mg) in the treatment of bacterial vaginosis

Next Previous
X
Search
Trial Profile

Comparative study of the efficacy and safety of vaginally applied Dequalinium Chloride (10 mg) and orally applied Metronidazole (2 x 500 mg) in the treatment of bacterial vaginosis

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dequalinium (Primary) ; Metronidazole
  • Indications Bacterial vaginosis
  • Focus Therapeutic Use
  • Sponsors Medinova

    • Most Recent Events

    • 28 Mar 2023 Status changed to discontinued.
    • 05 Nov 2022 This trial has been discontinued in Slovakia (Date of the global end of the trial : 25-Aug-2022), according to European Clinical Trials Database record.
    • 11 May 2022 Planned number of patients changed from 320 to 236.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top